INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145201, 'Guanadrel', 'Norepinephrine', 'Moderate', 'Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished. Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.', 'DDInter', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension. Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines. If the combination is used, blood pressure and heart rate should be closely monitored.', 'Synergism', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145364/', '', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145202, 'Guanethidine', 'Norepinephrine', 'Moderate', 'Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished. Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.', 'DDInter', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension. Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines. If the combination is used, blood pressure and heart rate should be closely monitored.', 'Synergism', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145365/', '', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine', 'Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145203, 'Halothane', 'Norepinephrine', 'Major', 'The combination of norepinephrine and some anesthetics has resulted in ventricular irritability, serious cardiac arrhythmias, or death. The halogenated anesthetics sensitize the heart to the arrhythmogenic effects of catecholamines.', 'DDInter', 'This combination should be avoided or used very cautiously. If a halogenated anesthetic and norepinephrine must be used together, very low doses of norepinephrine concentrations are recommended and the patient''s hemodynamic status should be closely monitored.', 'Others', 'This combination should be avoided or used very cautiously.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145366/', '', 'Dobutamine, Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Fenoldopam, Metaraminol, Dopamine, More', 'Thiopental, Alfentanil, Remifentanil, Sodium oxybate, Methohexital, Fentanyl, Nitrous oxide, Sufentanil, Propofol, Esketamine, Etomidate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145204, 'Imipramine', 'Norepinephrine', 'Major', 'Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.', 'DDInter', 'Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis). If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely. Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.', 'Synergism', 'Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145367/', '', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Fenoldopam, Mephentermine', 'Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145205, 'Indacaterol', 'Norepinephrine', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', 'DDInter', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145368/', '', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145206, 'Indomethacin', 'Norepinephrine', 'Minor', 'Limited data have shown that indomethacin may enhance the pressor response to norepinephrine. Eicosanoids originating from the cyclooxygenase pathway of arachidonate metabolism may modulate the vascular response to adrenergic stimulation. Indomethacin is a potent cyclooxygenase inhibitor. The clinical significance is unknown. Blood pressure monitoring is recommended during norepinephrine infusion, particularly in patients who have used or are taking indomethacin.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145369/', '', 'Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Diclofenac, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Dexamethasone, Rabeprazole, Ketoprofen, More', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Isoprenaline, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145207, 'Insulin human', 'Norepinephrine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145370/', '', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145208, 'Insulin aspart (aspart protamine)', 'Norepinephrine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145371/', '', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145209, 'Insulin lispro', 'Norepinephrine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145372/', '', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145210, 'Insulin lispro (protamine)', 'Norepinephrine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145373/', '', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145211, 'Insulin human (zinc)', 'Norepinephrine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145374/', '', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145212, 'Insulin human (zinc extended)', 'Norepinephrine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145375/', '', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145213, 'Isoetharine', 'Norepinephrine', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', 'DDInter', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145376/', '', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Metaraminol, Methoxamine, Mephentermine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145214, 'Norepinephrine', 'Ketamine', 'Moderate', 'Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index. Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.', 'DDInter', 'Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145377/', '', 'Arbutamine, Amrinone, Milrinone, Angiotensin II', 'Thiopental, Alfentanil, Remifentanil, Sodium oxybate, Methohexital, Fentanyl, Nitrous oxide, Sufentanil, Propofol, Esketamine, Etomidate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145215, 'Norepinephrine', 'Levobetaxolol (ophthalmic)', 'Moderate', 'Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', 'DDInter', 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.', 'Antagonism', 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145378/', '', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Metaraminol, Methoxamine, Mephentermine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145216, 'Norepinephrine', 'Mazindol', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', 'DDInter', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145379/', '', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Metaraminol, Methoxamine, Mephentermine', 'Dexfenfluramine, Naltrexone, Ephedrine, Fenfluramine, Orlistat, Lorcaserin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145217, 'Norepinephrine', 'Methoxyflurane', 'Major', 'The combination of norepinephrine and some anesthetics has resulted in ventricular irritability, serious cardiac arrhythmias, or death. The halogenated anesthetics sensitize the heart to the arrhythmogenic effects of catecholamines.', 'DDInter', 'This combination should be avoided or used very cautiously. If a halogenated anesthetic and norepinephrine must be used together, very low doses of norepinephrine concentrations are recommended and the patient''s hemodynamic status should be closely monitored.', 'Others', 'This combination should be avoided or used very cautiously.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145380/', '', 'Dobutamine, Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', 'Salicylic acid, Acetaminophen, Choline salicylate, Ziconotide, Diflunisal, Salsalate, Acetylsalicylic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145218, 'Norepinephrine', 'Methysergide', 'Major', 'Additive or synergistic increases in blood pressure and/or ischemic response may occur when ergot alkaloids are combined with peripheral or central vasoconstrictors. Ergot alkaloids produce arterial vasoconstriction by stimulating alpha-adrenergic and serotonin receptors and inhibiting endothelial-derived relaxation factor release.', 'DDInter', 'Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents. If concomitant use is required, patients should be monitored for excessive vasoconstriction and have vital signs measured regularly. Patients should also be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.', 'Synergism', 'Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145381/', '', 'Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Naratriptan, Galcanezumab, Zolmitriptan, More', 'Dobutamine, Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Isoprenaline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145219, 'Nortriptyline', 'Norepinephrine', 'Major', 'Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.', 'DDInter', 'Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis). If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely. Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.', 'Synergism', 'Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145382/', '', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Mephentermine', 'Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145220, 'Opicapone', 'Norepinephrine', 'Moderate', 'COMT inhibitors affect the elimination of drugs metabolized by catechol-O-methyltransferase (COMT) and may potentiate their effects. Arrhythmias, increased heart rate, and blood pressure changes may occur. Entacapone has increased heart rates up to 80% when coadministered with isoproterenol and epinephrine. Ventricular tachycardia has also been reported.', 'DDInter', 'The manufacturer recommends that caution be exercised when these drugs are given together. Monitoring for changes in hemodynamic status and ECG is recommended.', 'Metabolism', 'The manufacturer recommends that caution be exercised when these drugs are given together.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145383/', '', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Methoxamine, Mephentermine', 'Apomorphine, Ropinirole, Cabergoline, Amantadine, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Safinamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145221, 'Oxytocin', 'Norepinephrine', 'Moderate', 'Concomitant use of oxytocic agents with sympathomimetic amines may increase the risk of hypertension due to additive vasoconstrictive effects. Severe hypertension and headache have been reported when oxytocin was given 3 to 4 hours following prophylactic administration of a vasoconstrictor in conjunction with caudal block anesthesia.', 'DDInter', 'Close monitoring of blood pressure is recommended during coadministration.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145384/', '', 'Misoprostol, Dinoprostone, Terlipressin', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145222, 'Ozanimod', 'Norepinephrine', 'Moderate', 'While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together. Some cases of increased heart rate and blood pressure have been reported.', 'DDInter', 'Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).', 'Synergism', 'Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145385/', '', 'Arbutamine, Angiotensin II', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145223, 'Penbutolol', 'Norepinephrine', 'Moderate', 'Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', 'DDInter', 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.', 'Antagonism', 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145386/', '', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145224, 'Phendimetrazine', 'Norepinephrine', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', 'DDInter', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145387/', '', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145225, 'Phenelzine', 'Norepinephrine', 'Moderate', 'While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together. Some cases of increased heart rate and blood pressure have been reported.', 'DDInter', 'Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).', 'Synergism', 'Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145388/', '', 'Arbutamine, Angiotensin II', 'Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145226, 'Phenylpropanolamine', 'Norepinephrine', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', 'DDInter', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145389/', '', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 'Pseudoephedrine, Phenylephrine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145227, 'Pindolol', 'Norepinephrine', 'Moderate', 'Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', 'DDInter', 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.', 'Antagonism', 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145390/', '', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145228, 'Pramlintide', 'Norepinephrine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145391/', '', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145229, 'Procarbazine', 'Norepinephrine', 'Moderate', 'While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together. Some cases of increased heart rate and blood pressure have been reported.', 'DDInter', 'Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).', 'Synergism', 'Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145392/', '', 'Arbutamine, Angiotensin II', 'Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145230, 'Propranolol', 'Norepinephrine', 'Moderate', 'Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', 'DDInter', 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.', 'Antagonism', 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145393/', '', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine', 'Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145231, 'Protriptyline', 'Norepinephrine', 'Major', 'Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.', 'DDInter', 'Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis). If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely. Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.', 'Synergism', 'Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145394/', '', 'Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Mephentermine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145232, 'Racepinephrine', 'Norepinephrine', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', 'DDInter', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145395/', '', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145233, 'Rasagiline', 'Norepinephrine', 'Moderate', 'While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together. Some cases of increased heart rate and blood pressure have been reported.', 'DDInter', 'Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).', 'Synergism', 'Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145396/', '', 'Droxidopa, Arbutamine, Angiotensin II', 'Apomorphine, Ropinirole, Cabergoline, Amantadine, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Safinamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145234, 'Reserpine', 'Norepinephrine', 'Moderate', 'Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished. Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.', 'DDInter', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension. Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines. If the combination is used, blood pressure and heart rate should be closely monitored.', 'Synergism', 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145397/', '', 'Prazosin, Clonidine, Hydralazine, Guanfacine, Clonidine', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145235, 'Ritodrine', 'Norepinephrine', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', 'DDInter', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145398/', '', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 'Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145236, 'Rosiglitazone', 'Norepinephrine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145399/', '', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145237, 'Salmeterol', 'Norepinephrine', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', 'DDInter', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145400/', '', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145238, 'Selegiline', 'Norepinephrine', 'Moderate', 'While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together. Some cases of increased heart rate and blood pressure have been reported.', 'DDInter', 'Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).', 'Synergism', 'Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145401/', '', 'Droxidopa, Arbutamine, Angiotensin II', 'Apomorphine, Ropinirole, Cabergoline, Amantadine, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Safinamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145239, 'Sevoflurane', 'Norepinephrine', 'Major', 'The combination of norepinephrine and some anesthetics has resulted in ventricular irritability, serious cardiac arrhythmias, or death. The halogenated anesthetics sensitize the heart to the arrhythmogenic effects of catecholamines.', 'DDInter', 'This combination should be avoided or used very cautiously. If a halogenated anesthetic and norepinephrine must be used together, very low doses of norepinephrine concentrations are recommended and the patient''s hemodynamic status should be closely monitored.', 'Others', 'This combination should be avoided or used very cautiously.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145402/', '', 'Dobutamine, Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', 'Thiopental, Alfentanil, Remifentanil, Sodium oxybate, Methohexital, Fentanyl, Nitrous oxide, Sufentanil, Propofol, Esketamine, Etomidate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145240, 'Sibutramine', 'Norepinephrine', 'Moderate', 'Additive or synergistic effects on blood pressure and heart rate may occur when sibutramine is combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors. Sibutramine is a potent inhibitor of norepinephrine and serotonin reuptake, and a less potent inhibitor of dopamine reuptake.', 'DDInter', 'Caution is advised if sibutramine is coadministered with other drugs that can increase blood pressure and/or heart rate. Blood pressure and pulse should be measured prior to initiating therapy with sibutramine and monitored at regular intervals thereafter. Dose reduction or discontinuation of sibutramine should be considered in patients who experience a sustained increase in blood pressure or pulse rate.', 'Synergism', 'Caution is advised if sibutramine is coadministered with other drugs that can increase blood pressure and/or heart rate.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145403/', '', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 'Dexfenfluramine, Naltrexone, Ephedrine, Fenfluramine, Orlistat, Lorcaserin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145241, 'Solriamfetol', 'Norepinephrine', 'Moderate', 'Additive or synergistic effects on blood pressure and/or heart rate may occur when solriamfetol is combined with other drugs that increase blood pressure and/or heart rate. The use of solriamfetol alone has been associated with dose-dependent increases in blood pressure and heart rate.', 'DDInter', 'Caution is advised if solriamfetol is used with other drugs that increase blood pressure and/or heart rate. Blood pressure should be monitored prior to initiating solriamfetol therapy and regularly during treatment. In addition, hypertension should be controlled prior to treatment, and any new-onset hypertension or exacerbations of pre-existing hypertension that occur during solriamfetol therapy should be treated. Discontinuation of solriamfetol should be considered in patients who experience an increase in blood pressure or heart rate that cannot be managed with dose reduction of solriamfetol or other appropriate medical intervention.', 'Synergism', 'Caution is advised if solriamfetol is used with other drugs that increase blood pressure and/or heart rate.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145404/', '', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 'Pemoline, Caffeine, Armodafinil, Citicoline, Modafinil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145242, 'Sotalol', 'Norepinephrine', 'Moderate', 'Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', 'DDInter', 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.', 'Antagonism', 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145405/', '', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine', 'Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145243, 'Tapentadol', 'Norepinephrine', 'Moderate', 'Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors. The use of SNRIs alone has been associated with sustained increases in blood pressure and heart rate, and cases of elevated blood pressure requiring immediate treatment have been reported in postmarketing experience.', 'DDInter', 'Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate. Blood pressure and pulse should be measured prior to initiating SNRI therapy and monitored at regular intervals thereafter. Dose reduction or discontinuation of the SNRI should be considered in patients who experience a sustained increase in blood pressure or pulse rate.', 'Synergism', 'Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145406/', '', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 'Naltrexone, Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Oliceridine, Morphine, Butorphanol, Fentanyl, Ibuprofen, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145244, 'Terbutaline', 'Norepinephrine', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', 'DDInter', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145407/', '', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 'Ephedrine, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145245, 'Timolol', 'Norepinephrine', 'Moderate', 'Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', 'DDInter', 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.', 'Antagonism', 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145408/', '', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine', 'Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145246, 'Tolazamide', 'Norepinephrine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145409/', '', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145247, 'Tolbutamide', 'Norepinephrine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145410/', '', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 'Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Macimorelin, Methacholine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145248, 'Tolcapone', 'Norepinephrine', 'Moderate', 'COMT inhibitors affect the elimination of drugs metabolized by catechol-O-methyltransferase (COMT) and may potentiate their effects. Arrhythmias, increased heart rate, and blood pressure changes may occur. Entacapone has increased heart rates up to 80% when coadministered with isoproterenol and epinephrine. Ventricular tachycardia has also been reported.', 'DDInter', 'The manufacturer recommends that caution be exercised when these drugs are given together. Monitoring for changes in hemodynamic status and ECG is recommended.', 'Metabolism', 'The manufacturer recommends that caution be exercised when these drugs are given together.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145411/', '', 'Apomorphine, Ropinirole, Cabergoline, Amantadine, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Safinamide', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Methoxamine, Mephentermine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145249, 'Tranylcypromine', 'Norepinephrine', 'Moderate', 'While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together. Some cases of increased heart rate and blood pressure have been reported.', 'DDInter', 'Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).', 'Synergism', 'Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145412/', '', 'Arbutamine, Angiotensin II', 'Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145250, 'Trimipramine', 'Norepinephrine', 'Major', 'Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.', 'DDInter', 'Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis). If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely. Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.', 'Synergism', 'Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145413/', '', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Mephentermine', 'Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145251, 'Troglitazone', 'Norepinephrine', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145414/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Metaraminol, Methoxamine, Mephentermine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145252, 'Vasopressin', 'Norepinephrine', 'Moderate', 'Concomitant use of vasopressin or desmopressin with catecholamines is expected to result in an additive effect on mean arterial blood pressure and other hemodynamic parameters. In addition, although the combination noradrenaline (norepinephrine) and vasopressin is clinically used to improve hemodynamic parameters, noradrenaline may also decrease the antidiuretic effect of vasopressin.', 'DDInter', 'The use of injectable vasopressin or large doses of intranasal or oral desmopressin with other pressor agents should only be done with careful hemodynamic monitoring. Vasopressin dosage may need to be adjusted. Consulting local protocols with respect to the dosage of vasopressin and the order of administration when used with noradrenaline is encouraged.', 'Synergism', 'The use of injectable vasopressin or large doses of intranasal or oral desmopressin with other pressor agents should only be done with careful hemodynamic monitoring.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145415/', '', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Methoxamine, Mephentermine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145253, 'Venlafaxine', 'Norepinephrine', 'Moderate', 'Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors. The use of SNRIs alone has been associated with sustained increases in blood pressure and heart rate, and cases of elevated blood pressure requiring immediate treatment have been reported in postmarketing experience.', 'DDInter', 'Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate. Blood pressure and pulse should be measured prior to initiating SNRI therapy and monitored at regular intervals thereafter. Dose reduction or discontinuation of the SNRI should be considered in patients who experience a sustained increase in blood pressure or pulse rate.', 'Synergism', 'Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145416/', '', 'Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145254, 'Abarelix', 'Norfloxacin', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', 'DDInter', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145417/', '', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145255, 'Acetohexamide', 'Norfloxacin', 'Major', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.', 'DDInter', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.', 'Antagonism', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145418/', '', 'Guar gum', 'Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145256, 'Aluminum hydroxide', 'Norfloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145419/', '', 'Tinidazole, Fluconazole, Cefepime, Metronidazole, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145257, 'Aminolevulinic acid', 'Norfloxacin', 'Major', 'Patients exposed to photosensitizing agents may be at increased risk of a phototoxic skin reaction (severe sunburn) during use of aminolevulinic acid.', 'DDInter', 'Photosensitizing agents (e.g., fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, St. John''s wort) and topical preparations containing aminolevulinic acid should generally not be administered for 24 hours before and after oral administration of aminolevulinic acid.', 'Synergism', 'Photosensitizing agents (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145420/', '', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More', 'Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145258, 'Aminophylline', 'Norfloxacin', 'Moderate', 'Some fluoroquinolones have been shown to decrease the hepatic metabolism of theophyllines. The mechanism is inhibition of CYP450 1A2 hepatic metabolism. Patients with chronic obstructive pulmonary disease, congestive heart failure, or cirrhosis may have slower theophylline clearance rates; therefore, they may be at greater risk of developing theophylline toxicity. This drug combination may increase the risk of seizures, especially in the elderly. Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels during concurrent fluoroquinolone therapy.', 'DDInter', 'Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels. Levofloxacin, sparfloxacin, and lomefloxacin have been reported to cause minor or no changes in theophylline levels and may be considered as alternatives. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeat to their physicians.', 'Metabolism', 'Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145421/', '', 'Tinidazole, Secnidazole, Cefixime, Amikacin, Levofloxacin, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Netilmicin, More', 'Omalizumab, Tezepelumab, Benralizumab, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145259, 'Amoxapine', 'Norfloxacin', 'Moderate', 'Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145422/', '', 'Phenelzine, Tranylcypromine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More', 'Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145260, 'Anisindione', 'Norfloxacin', 'Major', 'Some quinolone antibiotics have been reported to potentiate the hypoprothrombinemic effect of warfarin and other coumarin anticoagulants. The exact mechanism is unknown but may involve inhibition of coumarin metabolism and/or depletion of certain clotting factors due to suppression of vitamin K-producing intestinal flora.', 'DDInter', 'Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy. The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of quinolone therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones), although clinical data are lacking.', 'Others', 'Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145423/', '', 'Amikacin, Secnidazole, Ganciclovir, Acyclovir, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Lomefloxacin, Famciclovir, Trifluridine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145261, 'Norfloxacin', 'Astemizole', 'Moderate', 'Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145424/', '', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More', 'Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145262, 'Attapulgite', 'Norfloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145425/', '', 'Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More', 'Pectin, Activated charcoal', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145263, 'Bedaquiline', 'Norfloxacin', 'Major', 'Bedaquiline can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if bedaquiline is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting bedaquiline therapy and periodically during treatment in accordance with the product labeling. Hypokalemia, hypomagnesemia, and hypocalcemia must be corrected prior to bedaquiline administration.', 'Synergism', 'Caution is recommended if bedaquiline is used in combination with other drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145426/', '', 'Tinidazole, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, More', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Rifampicin, Cycloserine, Rifabutin, Ethambutol, Pyridoxine, Ethionamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145264, 'Bepridil', 'Norfloxacin', 'Major', 'Quinolones such as ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, and sparfloxacin may cause dose-related prolongation of the QT interval in some patients. Coadministration with other agents that can prolong the QT interval may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential related to their effects on cardiac conduction.', 'DDInter', 'Product labeling for certain quinolones recommends avoiding concomitant therapy with class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents, as well as bepridil.', 'Synergism', 'Product labeling for certain quinolones recommends avoiding concomitant therapy with class IA (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145427/', '', 'Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145265, 'Bifidobacterium longum infantis', 'Norfloxacin', 'Moderate', 'INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.', 'DDInter', 'Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145428/', '', 'Tinidazole, Fluconazole, Cefepime, Amikacin, Ganciclovir, Acyclovir, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Famciclovir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145266, 'Bromfenac', 'Norfloxacin', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.', 'DDInter', 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145429/', '', 'Fluocinolone acetonide, Fluorometholone', 'Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Rifamycin, Lomefloxacin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145267, 'Calcium carbonate', 'Norfloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145430/', '', 'Tinidazole, Fluconazole, Cefepime, Metronidazole, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, Ampicillin, More', 'Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145268, 'Calcium citrate', 'Norfloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145431/', '', 'Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More', 'Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145269, 'Calcium glubionate anhydrous', 'Norfloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145432/', '', 'Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More', 'Calcium glucoheptonate, Calcium chloride', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145270, 'Calcium gluconate', 'Norfloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145433/', '', 'Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More', 'Calcium glucoheptonate, Calcium chloride, Minoxidil, Deoxycholic acid, Pimecrolimus, Glycopyrronium, Aminobenzoic acid, Finasteride, Ivermectin, Cromoglicic acid, Abrocitinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145271, 'Calcium glycerophosphate', 'Norfloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145434/', '', 'Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145272, 'Calcium lactate', 'Norfloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145435/', '', 'Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More', 'Calcium glucoheptonate, Calcium chloride', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145273, 'Iron', 'Norfloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145436/', '', 'Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More', 'Iron sucrose, Cyanocobalamin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145274, 'Frangula purshiana bark', 'Norfloxacin', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', 'DDInter', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145437/', '', 'Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145275, 'Castor oil', 'Norfloxacin', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', 'DDInter', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145438/', '', 'Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, More', 'Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145276, 'Chlorpromazine', 'Norfloxacin', 'Moderate', 'Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145439/', '', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145277, 'Chromium picolinate', 'Norfloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145440/', '', 'Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145278, 'Cisapride', 'Norfloxacin', 'Major', 'Cisapride can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145441/', '', 'Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145279, 'Copper gluconate', 'Norfloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145442/', '', 'Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145280, 'Cytarabine', 'Norfloxacin', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145443/', '', 'Cladribine, Trifluridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine, Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, More', 'Tinidazole, Cefixime, Tetracycline, Secnidazole, Tetracycline, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145281, 'Dacarbazine', 'Norfloxacin', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145444/', '', 'Tinidazole, Tetracycline, Cefepime, Metronidazole, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, Ampicillin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145282, 'Dicoumarol', 'Norfloxacin', 'Major', 'Some quinolone antibiotics have been reported to potentiate the hypoprothrombinemic effect of warfarin and other coumarin anticoagulants. The exact mechanism is unknown but may involve inhibition of coumarin metabolism and/or depletion of certain clotting factors due to suppression of vitamin K-producing intestinal flora.', 'DDInter', 'Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy. The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of quinolone therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones), although clinical data are lacking.', 'Others', 'Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145445/', '', 'Ticagrelor, Betrixaban, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, More', 'Amikacin, Secnidazole, Ganciclovir, Acyclovir, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Lomefloxacin, Famciclovir, Trifluridine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145283, 'Diflunisal', 'Norfloxacin', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.', 'DDInter', 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145446/', '', 'Ziconotide, Methoxyflurane', 'Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Rifamycin, Ampicillin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145284, 'Doxorubicin (liposomal)', 'Norfloxacin', 'Moderate', 'Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145447/', '', 'Ixabepilone, Valrubicin', 'Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145285, 'Entecavir', 'Norfloxacin', 'Moderate', 'Coadministration of entecavir with another drug that is also eliminated by active tubular secretion may result in increased plasma concentrations of one or both drugs due to competitive inhibition of transporters in the renal tubules. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.', 'DDInter', 'Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.', 'Excretion', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145448/', '', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Secnidazole, Azithromycin, Tetracycline, Rifamycin, Oxytetracycline, Sulfamethizole, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145286, 'Entrectinib', 'Norfloxacin', 'Moderate', 'Entrectinib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of entrectinib with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have electrocardiograms (ECGs) performed prior to initiation of entrectinib and periodically during treatment as appropriate based on individual risk factors.', 'Synergism', 'Coadministration of entrectinib with other drugs that can prolong the QT interval should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145449/', '', 'Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More', 'Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145287, 'Enzalutamide', 'Norfloxacin', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', 'DDInter', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145450/', '', 'Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, More', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145288, 'Epirubicin', 'Norfloxacin', 'Moderate', 'Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145451/', '', 'Ixabepilone, Valrubicin', 'Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145289, 'Eribulin', 'Norfloxacin', 'Moderate', 'Eribulin may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if eribulin is used in combination with other drugs that can prolong the QT interval. Baseline and periodic monitoring of electrocardiograms and serum electrolytes (potassium, magnesium) should be considered, and hypokalemia or hypomagnesemia corrected prior to initiating treatment with eribulin. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if eribulin is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145452/', '', 'Tetracycline, Cefepime, Cefuroxime, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, More', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145290, 'Ertugliflozin', 'Norfloxacin', 'Moderate', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.', 'DDInter', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.', 'Antagonism', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145453/', '', 'Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More', 'Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145291, 'Escitalopram', 'Norfloxacin', 'Major', 'Escitalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Caution is recommended if escitalopram is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. When escitalopram is used in combination with other drugs that cause CNS and/or respiratory depression, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Caution is recommended if escitalopram is used in combination with other drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145454/', '', 'Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More', 'Phenelzine, Tranylcypromine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145292, 'Etacrynic acid', 'Norfloxacin', 'Minor', 'The plasma concentration of lomefloxacin following administration of furosemide has been reported to be higher than after lomefloxacin alone. The area under the curve of lomefloxacin was increased and the total and renal clearances of lomefloxacin were decreased. A similar interaction may occur if other quinolones are administered with other loop diuretics. The loop diuretic may decrease the renal clearance of the quinolone by competing for tubular secretion.', 'DDInter', '-', 'Excretion', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145455/', '', 'Tinidazole, Fluconazole, Metronidazole, Secnidazole, Azithromycin, Levofloxacin, Gatifloxacin, Acyclovir, Rifamycin, Ganciclovir, Famciclovir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145293, 'Etodolac', 'Norfloxacin', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.', 'DDInter', 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145456/', '', 'Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine', 'Tinidazole, Tetracycline, Cefepime, Metronidazole, Secnidazole, Cefixime, Tetracycline, Ganciclovir, Rifamycin, Oxytetracycline, Polymyxin B, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145294, 'Etoposide', 'Norfloxacin', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145457/', '', 'Trabectedin, Cabazitaxel', 'Tetracycline, Cefixime, Azithromycin, Tetracycline, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145295, 'Exenatide', 'Norfloxacin', 'Moderate', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.', 'DDInter', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.', 'Antagonism', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145458/', '', 'Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Tetracycline, Ganciclovir, More', 'Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145296, 'Ezogabine', 'Norfloxacin', 'Moderate', 'Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145459/', '', 'Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More', 'Brivaracetam, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, Perampanel, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145297, 'Fenoprofen', 'Norfloxacin', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.', 'DDInter', 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145460/', '', 'Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine', 'Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Rifamycin, Ampicillin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145298, 'Tetraferric tricitrate decahydrate', 'Norfloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145461/', '', 'Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145299, 'Ferrous fumarate', 'Norfloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145462/', '', 'Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More', 'Iron sucrose, Cyanocobalamin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (145300, 'Ferrous gluconate', 'Norfloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/145463/', '', 'Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More', 'Iron sucrose, Cyanocobalamin', 1767369485);
